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Objective: To investigatewhether number of doses per day andnumber ofmedications are signiﬁcantly associated
with the number of readmissions and to study the association of readmission frequency with other medical and
socio-demographic variables.
Methods: Retrospective cross-sectional study involving 432 patients who were readmitted within 15 days of
previous hospital discharge between January 1, 2013 andMarch 31, 2013. Relevant medical records were collected
from the national electronic databases of every public tertiary hospital in Singapore. Signiﬁcant variables (p b 0.05)
were identiﬁed using forward selection and modeled using generalized linear mixed models.
Results: A total of 649 unplanned readmissions were reviewed. At amultivariable level, number of readmission was
signiﬁcantly associatedwith the number ofmedications (p= 0.002) andnumber of doses per day (p= 0.003) after
adjusting for race, liver disease, schizophrenia and non-compliance.
Conclusion: Complex medication regimen (i.e. multiple medications and multiple doses per day) is a statistically
signiﬁcant predictor of number of readmissions. Simplifying therapeutic regimens with alternatives such as
longer-acting or ﬁxed-dose combination drugs may facilitate better patient adherence and reduce costly
readmissions.© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-SA license
(http://creativecommons.org/licenses/by-nc-sa/3.0/).Introduction
Unplanned readmission is a costly and largely preventable healthcare
burden. In their landmark article, Jencks et al. revealed that readmissions
account for an estimated USD17.4 billion in annual spending by Medi-
care (US) (Jencks et al., 2009). Reducing readmission rates has become
an imperative among healthcare policymakers. In the United States, the
Affordable Care Act authorizes Medicare to impose reimbursement pen-
alties on hospitals for excessive readmissions (Kocher andAdashi, 2011).
Causes of readmissions are multi-factorial and many interventions
targeted at high-risk patients have been attempted hitherto, albeit with
varying degree success (Hansen et al., 2011).
Increased age, multiple comorbidities and polypharmacy, widely
deﬁned as the use of ﬁve or more drugs, have been identiﬁed as contri-
butory factors with the highest risk of readmission Kansagara et al.oo Teck Puat Hospital, 90 Yishun
.Z.Y. Tan).
. This is an open access article under(2011), Viktil et al. (2007). While age and the presence of comorbidities
are unmodiﬁable, polypharmacy may be addressed via a variety of ways
such as medication reconciliation and adoption of judicious prescribing
strategies Hanlon et al. (1996). A recent study on medication discontin-
uation among elderly patients successfully discontinued 311 medica-
tions in 64 patients without recurrence or worsening of clinical
symptoms. However, as acknowledged by the authors, most of the
discontinued medications were clearly inappropriate thus reasonably
discontinued (Garﬁnkel and Mangin, 2010). Such practice may not
always be feasible.
Relatedly, the reduction of dosing frequencies, hence number of
doses per day, was suggested as an alternative strategy where drug dis-
continuation may engender adverse outcomes (Garﬁnkel and Mangin,
2010; Fulton and Riley Allen, 2005). Prescriptions with less frequent
dosing regimens have been shown to decrease the occurrence of dis-
eases or symptomatology associated with the drug therapy (i.e. drug-
related problems (DRPs)) (Schoonover, 2012; Ingersoll and Cohen,
2008; Strand et al., 1990). However, the association between number of
doses per day and readmission frequency remains unclear. The present
study investigates the association between number of doses per day
and the number of readmissions.the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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Study design
We performed a retrospective, cross-sectional study involving 432
patients who had at least one readmission between January 1, 2013
and March 31, 2013. Institutional review board approval and waiver of
consent were obtained from the National Healthcare Group, Singapore.
Patient population
Subjects included patients from a general and acute care hospital in
Singapore. Patients who were 18 years and above and readmitted to
any public hospital in Singapore within the deﬁned study period were
included in the study. Subjects with inaccessible medical records were
excluded from the study.
Data collection
All data were collected through the national electronic medical
records database, a shared database across all public healthcare institu-
tions in Singapore. Readmissionwas deﬁned as each unscheduled admis-
sion occurring within 15 days of discharge. For patients with multiple
readmissions, each episode was counted as a separate readmission.
Details recorded for each readmission included age, sex, race, pres-
ence of speciﬁc co-morbidities from the Charlson Comorbidity Index
(Charlson et al., 1987), number of readmissions, number of medications
and number of doses per day dispensed during the previous discharge.
Total number ofmedications included all dispensedmedications of differ-
ent dosage forms or active ingredients. Different dosage forms containing
the same active ingredient were counted as separate medications. For
instance, a patient using betamethasone cream and betamethasone oint-
ment was considered to have been prescribed two different medications.
Different amounts per dosage unit of the same active ingredient in the
samedosage formwere not counted separately if theywere administered
with the same dosing frequency. For example, a patient taking one 5 mg
enalapril tablet twice daily and one 10mg enalapril tablet twice dailywas
considered to be taking only one medication with 2 doses per day.
Number of doses per day referred to the cumulative number of doses
for all dispensed medications per day. Doses of medications prescribed
on an ‘as needed’ basis were tabulated based on the maximum number
of prescribed doses per day. For example, “two 500mg paracetamol tab-
lets to be taken orally every 6 hourly as needed” was counted as four
doses of paracetamol 1 g per day. Doses prescribed on a non-daily dosing
schedule, such as once-weekly dose of alendronate, were recorded as a
single daily dose.
All readmission records were reviewed for DRPs diagnosed on admis-
sion. Readmission was treated as DRP-related only when it was explicitly
stated in the electronic case notes to be caused by a DRP. Documentation
of a DRP was based on implicit physician judgment. DRP categories were
adapted from those deﬁned by Strand et al. and include patient non-
compliance, over-dosage and sub-optimal dosage of the indicated medi-
cation and adverse drug reactions (Strand et al., 1990). Non-compliance
referred to the failure to adhere to the prescribed drug regimen in terms
of doses and dosing schedules (Vermeire et al., 2001).
Statistical analysis
Descriptive statistics was calculated and data was presented as
mean ± standard deviation or number and percentage. Univariate
regression analyses were performed to identify the prognostic
value of each variable in inﬂuencing the outcome of number of
readmissions in our study population. Variables which were found
to be signiﬁcantly (p b 0.05) associated with the outcome variable of
number of readmissions in the univariate analysis were subsequently
included in a multivariate regression model. Backward eliminationwas used to simplify the multivariate model, removing variables that
had a p value of ≥0.05 sequentially, until all remaining variables were
signiﬁcantly associated with the number of readmissions. To account
for non-independence and count nature of the dependent variable, gen-
eralized linear mixed models (GLMMs) with both Poisson and negative
binomial errors were used and compared. Multicollinearity was avoided
by ensuring variance inﬂation factor (VIF)was less than 3 throughout the
multivariable regression analyses. All statistical analyseswere carried out
using the R statistical programing language (version 3.0.1) and GLMMs
were ﬁtted using the GLMMadmb package (Fournier et al., 2012).
Results
There were a total of 649 unplanned readmissions during the study
period and most (66.6%) were ﬁrst-time readmissions. The mean age of
our sample was 67.7 ± 16.2 years. The mean number of doses per day
and number of medications were 18.0± 8.0 and 10.0± 4.4 respectively.
There is a total of 103 DRP-related readmissions, of which non-
compliance (5.6%) was the most common iatrogenic cause of readmis-
sion. Demographics and clinical characteristics of the readmission events
are summarized in Table 1.
Signiﬁcant univariable correlates (p b 0.05) include number of doses
per day, number of medications, race not of Chinese, Malay or Indian
race (classiﬁed as ‘other’ race), liver disease, anemia and schizophrenia,
as shown in Table 2.
There was no difference in results when GLMMs were modeled
using Poisson and negative binomial errors. From the GLMM analysis
using number of doses per day, factors that signiﬁcantly increased
the number of readmissions in the readmitted population were liver
disease (β= 0.33; p = 0.002), diagnosis of schizophrenia (β= 0.44;
p b 0.001), documented non-compliance (β= 0.32; p= 0.009), num-
ber of doses per day (β= 0.01; p= 0.003) and ‘other’ race (β= 0.25;
p= 0.02), as depicted in Table 3a. When the ‘number of doses per day’
variable was transformed and expressed in terms of number of medica-
tions prescribed, signiﬁcant variables were likewise, liver disease (β=
0.32; p = 0.003), diagnosis of schizophrenia (β = 0.44; p b0.001),
documented non-compliance (β = 0.32; p = 0.009) and ‘other’
race (β = 0.25; p = 0.02) and number of medications (β = 0.02;
p = 0.002), as seen in Table 3b.
Discussion
We found a signiﬁcant positive association between number of
readmissions and polypharmacy, expressed in terms of number of
doses per day and number of medications prescribed. In addition,
there was a signiﬁcant association between non-compliance and
the number of readmissions.
Non-compliance is among the most commonly reported iatrogenic
causes of readmission (33–69%) (Burke et al., 2000; Steinman, 2007;
Claxton et al., 2001). Our study supports this ﬁnding, with non-
compliance constituting 39 of the 103 DRP-related readmissions. Failure
to comply with dosage regimens can lead to suboptimal disease control
or rebound symptoms from abrupt cessation, requiring readmissions
(Garﬁnkel and Mangin, 2010). Barriers to medication adherence are
largely under the patient's control, with forgetfulness being the most
commonly cited (30%) (Osterberg and Blaschke, 2005). Practitioner-
led interventions such as regimen simpliﬁcation are useful in improving
compliance (Eisen et al., 1990). Evidence to date suggests that patients
adhere more to dosage regimens with fewer medications and in turn
are less likely to be hospitalized (Eisen et al., 1990; Col et al., 1990).
Unfortunately, combination therapies are indicated in patients with
multiple comorbidities especially if the diseases are poorly controlled
(Steinman, 2007; Lipton and Bero, 1992). For instance, the Joint National
Committee on Prevention, Detection, Evaluation and Treatment of High
Blood Pressure (JNC) recommends that 2 or more antihypertensive
drugs are required to achieve desired blood pressure levels (James et al.,
Table 2
Univariable regression with number of readmissions and variables.
Variables β (×10−2) 95% CI (×10−2) p value
Number of doses per day 1.23 0.45, 2.02 0.002
Number of medications 2.55 1.08, 4.02 b0.001
Age 0.029 −0.69, 0.12 0.16
Racea
If malay −0.04 −17.49, 17.41 1.00
If indian 17.40 −1.66, 36.46 0.07
If others 24.93 2.26, 47.60 0.03
Genderb
If female −3.00 −16.18, 10.18 0.66
Co-morbidities
Diabetes 12.84 −0.28, 25.96 0.06
Hypertension 8.44 −5.33, 22.21 0.23
Dyslipidemia 4.25 −8.93, 17.43 0.53
CHD 5.67 −19.87, 8.53 0.43
CVD −5.33 −24.99, 14.32 0.59
Hemiplegia 17.94 −41.65, 77.54 0.56
CHF −2.86 −33.15, 27.42 0.85
COPD 9.26 −16.89, 35.42 0.49
Asthma 15.80 −5.35, 36.95 0.14
Liver disease 29.61 7.34, 51.89 0.009
CKD −1.76 −22.06, 18.55 0.87
Ulcer disease −24.44 −54.38, 5.50 0.11
Osteoarthritis 7.14 −35.25, 20.98 0.62
Osteoporosis −7.59 −47.81, 32.63 0.71
Gout 3.85 −22.02, 29.73 0.77
Cataract 9.43 −17.29, 36.15 0.49
Anemia 16.45 1.29, 31.61 0.03
Cancer −14.57 32.83, 48.35 0.22
BPH 4.57 −22.05, 31.19 0.74
Thyroid disease −18.57 −50.61, 13.47 0.26
Hemorrhoid −0.15 −119.72, 119.41 1.00
Epilepsy 2.16 −7.93, 51.26 0.15
Dementia 16.65 −6.80, 40.11 0.16
Depression 13.23 −9.97, 36.42 0.26
Alzheimer's disease −21.25 −82.93, 40.44 0.5
Schizophrenia 38.75 11.43, 66.07 0.005
PKD −6.53 −46.66, 33.59 0.75
Non-compliance 25.20 −0.58, 50.91 0.06
Abbreviations: Coronary heart disease (CHD), chronic obstructive pulmonary disease
(COPD), cerebrovascular disease (CVD), congestive heart failure (CHF), chronic kidney
disease (CKD), benign prostatic hyperplasia (BPH) and Parkinson's disease (PKD).
Reference group:
a Chinese.
b Male.
Table 1
Demographics and clinical characteristics of events.
Variable Total number of events
(N = 649)
Age (years) 67.7 years ± 16.2
Race
Chinese 388 (59.8)
Malay 122 (18.8)
Indian 85 (13.1)
Others 54 (8.3)
Gender
Male 339 (52.2)
Female 310 (47.8)
Number of doses per day 18.0 ± 8.0
Number of medications 10.0 ± 4.4
Co-morbidities
Diabetes 299 (46.1)
Hypertension 411 (63.3)
Dyslipidemia 331 (51.0)
CHD 213 (32.8)
CVD 87 (13.4)
Hemiplegia 7 (1.1)
CHF 33 (5.1)
COPD 41 (6.3)
Asthma 63 (9.7)
Liver disease 50 (7.7)
CKD 79 (12.2)
Ulcer disease 40 (6.2)
Osteoarthritis 40 (6.2)
Osteoporosis 19 (2.9)
Gout 45 (6.9)
Cataract 39 (6.0)
Anemia 148 (22.8)
Cancer 62 (9.6)
BPH 41 (6.3)
Thyroid 33 (5.1)
Hemorrhoid 2 (0.3)
Epilepsy 29 (4.5)
Dementia 50 (7.7)
Depression 53 (8.2)
Alzheimer's disease 9 (1.4)
Schizophrenia 30 (4.6)
PKD 19 (2.9)
Types of DRPs
Non-compliance 39 (5.6)
Hypoglycemia 7 (0.9)
Hyponatremia 4 (0.6)
Hypokalemia 4 (0.6)
Metabolic alkalosis 1 (0.2)
Dehydration 7 (0.9)
Low blood pressure 5 (0.6)
Giddiness 5 (0.8)
LFT abnormalities 5 (0.8)
N/V/D 4 (0.6)
Constipation 1 (0.2)
Anemia 2 (0.3)
Thrombocytopenia 4 (0.6)
Rashes 4 (0.6)
Supratherapeutic dose 10 (1.5)
Subtherapeutic dose 1 (0.2)
Number of readmissions
1 432 (66.6)
2 135 (20.8)
3 46 (7.1)
4 21 (3.2)
5 8 (1.2)
6 5 (0.8)
7 1 (0.2)
8 1 (0.2)
Data shown as mean ± SD or n (%).
Abbreviations: Coronary heart disease (CHD), chronic obstructive pulmonary disease
(COPD), cerebrovascular disease (CVD), congestive heart failure (CHF), chronic kidney
disease (CKD) benign prostatic hyperplasia (BPH), Parkinson's disease (PKD), drug-related
problems (DRPs), liver function test (LFT), nausea, vomiting, diarrhea (N/V/D).
Table 3a
Generalized linearmixedmodel of number of readmissionswith number of doses per day.
Variables β (×10−2) 95% CI (×10−2) p value
Number of doses per day 1.14 0.38, 1.90 0.003
Racea
If Malay 0.81 −16.05, 17.67 0.92
If Indian 13.31 −5.12, 31.74 0.16
If others 24.69 3.42, 31.74 0.02
Co-morbidities
Liver disease 32.72 11.99, 53.44 0.002
Schizophrenia 44.17 19.17, 69.17 b0.001
Drug-related problemb
Non-compliance 31.75 7.94, 55.55 0.009
Reference group:
a Chinese.
b Absence of drug-related problem.
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increase patient's risk of severe hypotension necessitating emergency
visit and admission (Bangalore et al., 2007). Such a dilemma is notuncommon inother chronic conditionswherepolypharmacy is necessary
for disease control but is associated with undesired outcomes such as
readmissions, as seen in our study (Bangalore et al., 2007).
The indispensability of multi-drug therapies underscores the need
for alternative approaches to mitigate the heightened risks of non-
compliance and readmissions among patients with multiple comorbid-
ities. Reducing the total number of daily doses can effectively en-
courage patient adherence to their prescribed dosage regimen and
Table 3b
Generalized linear mixed model of number of readmissions with number of medications.
Variables β (×10−2) 95% CI (×10−2) p value
Number of medications 2.31 0.88, 3.73 0.002
Racea
If Malay 1.67 −15.19, 18.52 0.85
If Indian 13.32 −5.08, 31.75 0.16
If others 24.58 3.33, 45.82 0.02
Co-morbidities
Liver disease 31.66 10.90, 52.42 0.003
Schizophrenia 43.77 18.81, 68.74 b0.001
Drug-related problemb
Non-compliance 31.75 7.94, 55.56 0.009
Reference group:
a Chinese.
b Absence of drug-related problem.
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Claxton et al., 2001). In trials comparing once-daily and once-weekly
ﬂuoxetine, patients on once-weekly doses displayed greater adherence
rates (Claxton et al., 2000; Delgado, 2000). In a randomized-controlled
trial comparing once-daily gliclazidewith twice-daily glibenclamide,
fasting glucose and HbA1c were better controlled in patients on a
once-daily gliclazide regimen (Kardas, 2005).
Despite vast ﬁndings on the advantages of reducing number of doses
per day, there is no prior evidence on how this interventionwill improve
hospital readmission rates. From our study ﬁndings, readmission fre-
quency is positively correlated with number of doses per day. This sug-
gests that reducing dosing frequency through combination therapies
may minimize chances of unplanned readmissions. Undeniably, this
strategy is not always applicable, for example, when longer-acting alter-
natives are unavailable or unsuitable. In these instances, other compliance
measures such as constant reminders on the correct use of medications
andpatient involvement in the pharmaceutical care plan could be utilized
(Vermeire et al., 2001).
Readmission disparities among different races have been well-
documented among multiethnic populations (Joynt et al., 2011).
Among elderly Medicare (US) recipients, African Americans have
higher readmission rates compared to Caucasians (Joynt et al., 2011).
In comparison, our study found that only theminority race was a signif-
icant predictor of readmissions. These racial disparities may be due to
an underlying differential socio-economic status among the various
races (Russo et al., 2006; Laditka and Laditka, 2006).
Among the comorbidities, liver disease and schizophrenia were
signiﬁcantly associated with readmission at the multivariable level.
Liver diseases are complex with many complications such as hepatic
encephalopathy, ascites and portal hypertension requiring admission
(Berman et al., 2011; Agarwal et al., 1998). For schizophrenia, the
patient's lack of insight is a major barrier to adherence and contributor
to unplanned readmissions (Agarwal et al., 1998).
Limitations
Unlikemost studies listed in the systematic reviewbyKansagara et al.,
we used 15-day readmission instead of 30-day readmission as the study
outcome (Kansagara et al., 2011). More readmission events would have
been recorded had we used the 30-day readmission deﬁnition
(Goldﬁeld et al., 2008). This could have led to a potential underesti-
mation of the actual number of DRP-related readmissions. Here, the 15-
day cut-off was selected because readmissions within 15 days post-
discharge was already posing a signiﬁcant challenge to our healthcare
institution, with approximately 6 patients readmitted each day within
the deﬁned study period.
As the association between number of doses per day and hospital
readmission has never been reported, we conducted a retrospective
study to assess the feasibility of a subsequent prospective study. Due to
the retrospective study design, the electronic databases used in thisstudy did not contain data on illness severity and social determinants.
This is a common issue faced by other studies that relied on retrospective
administrative data. In a recent systematic review, only 2 out of a total 32
studies on prediction models of hospital readmission examined the
importance of disease severity (Kansagara et al., 2011). Of note, one of
the two studies which studied the disease severity found that it was a
signiﬁcant predictor (Burns and Nichols, 1991; Amarasingham et al.,
2010). Similarly, the predictive roles of socioeconomic status, education
and caregiver availability are poorly studied and remain largely inconclu-
sive (Kansagara et al., 2011). These variables will be considered in a
subsequent prospective study.
Conclusion
Readmissions can exert a heavy ﬁnancial burden on healthcare sys-
tems. Though the true proportion of preventable hospital readmissions
is not known, unplanned readmissions due to non-compliance can be
potentially preventable. In summary, we have demonstrated a positive
association between readmission frequency and polypharmacy, as well
as non-compliance. Prudent prescribing and the use of longer-acting for-
mulations or ﬁxed-dose combinations might minimize readmissions
attributable to non-compliance or polypharmacy, and achieve substantial
cost-savings.
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